



DOI: **10.5958/2249-7137.2021.02322.3**

CYTOKINE DIAGNOSTICS IN THE PROGNOSIS OF CRITICAL CONDITIONS IN NEWBORNS BORN TO MOTHERS INFECTED WITH COVID-19

Navruzova Shakar Istamovna*; Baratov Sunnat Samiyevich**

^{1,2}Bukhara State Medical Institute,
UZBEKISTAN

ABSTRACT

The authors conducted a study of cytokines of newborns born to mothers with coronavirus infection. SARS-CoV-2 infection causes a sharp decrease in the number of lymphocytes, especially a decrease in CD4 T cells, accompanied by uncontrolled release of inflammatory cytokines, which leads to a second stroke and exacerbates pathological changes in the respiratory system. Clinical symptoms vary among the infected population, suggesting that individual immune status is associated with susceptibility to COVID-19 and that immune dysfunction may play a significant role in the development of critical diseases.

KEYWORDS: COVID-19, SARS-Cov-2, Newborns, Critical Conditions, Coronavirus Disease, Cytokines

INTRODUCTION

The 2019 coronavirus disease (COVID-19) has spread rapidly around the world. With a sharp increase in the number of infections, the number of pregnant women and children with COVID-19 is also growing [6,23,24].

Since the first reported case of neonatal COVID-19 in February 2020 [20], concerns have been expressed about the possible vertical transmission of SARS-CoV-2 [9,10,12,23].

Early Chinese reports suggested that vertical transmission of SARS-CoV-2 does not occur because amniotic fluid, vaginal mucus, placenta, umbilical cord, umbilical cord blood and neonatal stool samples tested negative for the virus [6,7,11,15,17,19,21,24]. In addition, smears from the nasopharynx of these newborns immediately after delivery were negative. Moreover, there have been no reports of vertical transmission during outbreaks of Severe Acute Respiratory

Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) due to genetically similar coronaviruses [4,16].

In other series of cases, serological testing of seven newborns with limited postpartum exposure (mothers born by caesarean section wore masks, and newborns quickly separated from their mothers) showed the presence of virus-specific antibodies, including three with high IgM levels, despite negative virological testing [9,10]. This may indicate the transplacental passage of SARS-CoV-2, since IgM does not cross the placenta, although IgM assays are difficult to interpret due to frequent false positive results [12]. While postnatal transmission of infection to newborns is most likely, current data are inconclusive regarding intrauterine transmission [5].

It is known that critical conditions of newborns are characterized by organ dysfunction and multiple organ failure, the treatment of which requires urgent aggressive therapeutic measures. Changes in clinical, laboratory and physiological parameters in critical conditions are often considered and interpreted in isolation from each other. Timely adoption of clinical and organizational decisions in the treatment of patients in critical conditions is very important [1-3].

The frequency of critical diseases caused by COVID-19 is about 19%, of which in most cases progress to acute respiratory distress syndrome and respiratory failure, accompanied by acute immune dysfunction. SARS-CoV-2 infection causes a sharp decrease in the number of lymphocytes, especially a decrease in CD4 T cells, accompanied by uncontrolled release of inflammatory cytokines, which leads to a second stroke and exacerbates pathological changes in the respiratory system. Clinical symptoms vary among the infected population, suggesting that individual immune status is associated with susceptibility to COVID-19 and that immune dysfunction may play a significant role in the development of critical diseases. Due to the special immunological status of pregnant women, the inflammatory reaction of the mother to a coronavirus infection can affect the structural and functional development of the fetus and newborn [13,19].

In children, COVID-19 is weak or asymptomatic.¹²; however, the virus can remain in the body for a long time, and viral nucleic acids can persist in faeces, which suggests the possibility of non-respiratory transmission in children. Immaturity of immunological function in children and newborns leads to their increased susceptibility to viral infections, while immaturity of adaptive immunological development can make their clinical symptoms different from those in adults [8,13].

Together, these aspects raise serious questions about why the clinical manifestations of infected children and newborns differ from those of adults with immunosuppression and what effect the inflammatory response caused by maternal infection has on the immunological function of the fetus [14].

The aim of the study was to study blood and urine cytokines of newborns born to mothers infected with COVID-19 to predict the outcome of critical conditions.

Materials and methods of research:

Under observation were 120 newborns with critical conditions hospitalized in the BODMPMC in the period 2020-2021. A clinical and laboratory examination of 64 newborns was conducted: 33 newborns born to mothers with COVID-19 (group 1), 30 newborns with perinatal CNS lesion

(CNS) (2nd group) and 31 healthy newborns. The exclusion criteria were congenital malformations, prematurity, traumatic lesions of the central nervous system. All newborns underwent conventional clinical and laboratory methods of examination. To determine the molecular markers in the urine, the morning, first portion of urine was collected in special sterile plastic urine collectors with lids. Determination of the content of the main pro- and anti-inflammatory cytokines (IFN γ , IL-17A, MCP-1, IFN α , VEGF) in urine and serum (IFN γ , IL-17A, MCP-1, IFN α , VEGF) on the 5th day of life was carried out by solid-phase enzyme immunoassay using sets of reagents from Vector-Best (Novosibirsk, RF). The results were expressed in pg/ml. Statistical processing of the obtained results was carried out by methods of variational statistics using the Statistica for Windows application software package. Digital data was processed on an IB MPC personal computer using the memory of Microsoft Exell-97 application programs. The information was considered reliable under the condition that $t \geq 2$ and $P < 0.05$.

Research results and their discussion: To compare the immunological parameters of blood and urine, as well as to determine the dynamics of cytokines and reduce invasive procedures, the study of pro and anti-inflammatory cytokines in blood serum and urine in newborns was carried out. Modern literature says that the immune system in the neonatal period and in the postnatal period is in a state of physiological suppression. The biological meaning of suppressing immune reactions in newborns and in the postnatal period is to prevent the risk of developing severe immunopathological reactions with massive contact of the child with environmental antigens [8]. It has been established that the human immune system is inextricably linked with the interferon system. Interferons- α and - γ affect the activity of natural killers. Also, one of the important properties of interferons is the ability to interfere with intracellular replication of viruses, activating the cell's response to viral infection. Interferon triggers a cascade of biochemical reactions in cells that lead to suppression of the synthesis of viral proteins, as well as to suppression of the assembly and release of viral particles and activation of the process of apoptosis of an infected cell [3,22].

Prognostically unfavorable for the development of infectious and inflammatory diseases of the pulmonary system in premature infants is a decrease in the indicators of alpha and gamma interferons in the blood [4].

As a result of the analysis, it was found that the concentration of IFN γ increases in newborns of the 1st group to 23.64 ± 0.83 pkg/ml ($p < 0.05$), and in the 2nd group to 29.20 ± 1.28 pkg/ml ($p < 0.05$), in relation to the control 20.96 ± 0.66 pkg/ml (Table 1).

At the same time, an increase in the concentration of IFN α was also noted in newborns born to mothers with COVID-19 (group 1) to 33.71 ± 1.22 pkg/ml in relation to the control indicators 26.49 ± 1.20 pkg/ml ($p < 0.05$), and children of group 2 with PPCNS had a statistically insignificant decrease to 24.43 ± 1.36 pkg/ml.

TABLE 1 THE CONTENT OF CYTOKINES IN THE BLOOD OF NEWBORNS

Cytokines pg/ ml	Control groupn=31		1-groupn=33		2-groupn=30	
	min-max	Average	min-max	Average	min-max	Average
IFN γ	14,48- 27,35	20,96 \pm 0,66	15,27- 32,25	23,64 \pm 0,83*	17,05-39,63	29,20 \pm 1,28*
IFN α	15,83- 38,21	26,49 \pm 1,20	21,79- 47,37	33,71 \pm 1,22*	16,92-35,49	24,43 \pm 1,36
IL-17A	29,93- 64,97	46,99 \pm 1,70	55,34- 92,06	70,63 \pm 1,70*	24,22-56,17	38,74 \pm 2,07*
MCP-1	98,29- 305,71	196,69 \pm 9,9 2	422,15- 1058,15	765,66 \pm 33,07 *	74,22- 166,43	116,47 \pm 7,86*
VEGF	19,21- 59,93	38,47 \pm 2,23	25,17- 54,67	40,05 \pm 1,49	30,12-54,45	42,15 \pm 1,82

Note: *-significantly relative to the control ($p < 0.05$)

Consequently, the obtained results of studying the interferon status of observed newborns on the first 5th day of life show activation of interferon formation in full-term newborns born to mothers with COVID-19. Interleukin-17 belongs to proinflammatory cytokines and is involved in many stages of the immune response. It stimulates the production of chemokines and, as a result, stimulates the migration of neutrophils to the site of inflammation. IL-17 triggers an extensive tissue reaction leading to the migration of neutrophils into the inflammatory zone [7]. IL17A is a dimeric glycoprotein (15 kDa) consisting of 155 amino acids. Its biological function is aimed at ensuring the interaction between innate and acquired immunity [18,36].

The study of IL-17A levels in the serum of observed newborns showed a statistically significant increase in group 1 children to 70.63 ± 1.70 pg/ml ($p < 0.05$), and in group 2 a decrease to 38.74 ± 2.07 pg/ml ($p < 0.05$) versus control- 46.99 ± 1.70 pg/ml. The results obtained indicate the presence of an inflammatory process and activation of the phagocytosis system in the first 5 days of life in full-term newborns born to mothers with COVID-19. And a significant decrease in its level in newborns with PCNS confirms an increase in INF γ and the absence of inflammation. Thus, full-term newborns born to mothers with COVID-19 are characterized by an increase in the synthesis of INF γ and IFN α against the background of an increase in IL-17A, which confirms the activation of phagocytosis and interferon synthesis in response to viral load for the first time 5 days of life.

It is known that monocytic chemotactic protein (MCP-1) is widely involved in physiological (teething, nociception, angiogenesis, etc.) and pathophysiological processes in the body, participates in the pathogenesis of a number of diseases. MCP-1 is mainly expressed by macrophages in response to the action of a wide range of cytokines, such as IL-6, TNF- α and IL-1b. Due to its targeted cell specificity, it has been postulated that MCP-1 plays a pathogenic role in a variety of different diseases characterized by infiltration of mononuclear cells. Elevated levels of MCP-1 were also detected in connection with bone inflammation, as well as in myocardial ischemia and viral infection [5].

In our studies, when studying the concentration of MCP-1 in the blood serum of observed healthy and sick newborns with critical conditions, a statistically significant increase was found

in group 1 children to -765.66 ± 33.07 pg/ml ($p < 0.05$), and in group 2 a decrease to 116.47 ± 7.86 pg/ml ($p < 0.05$) versus control- 196.69 ± 9.92 pg/ml.

Consequently, the established increase in the level of MCP-1 in group 1 newborns confirms the development of inflammation at the endothelial level and indicates the onset of systemic inflammatory response syndrome (SIRS).

Currently, seven different CoV strains have been found to infect humans, including HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1, which usually cause self-resolving symptoms. In addition, coronavirus can cause severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS-CoV) and lethal acute respiratory syndrome, which causes the recently identified SARS-CoV-2. Four types of HCoV, including HCoV-229E (α -CoV), HCoV-NL63 (α -CoV), HCoV-OC43 (β -CoV) and HCoV-HKU1 (β -CoV), are endemic to humans and usually cause mild respiratory infection with self-resolving symptoms, which accounts for 15-30% of acute respiratory diseases (ARI). As a rule, this type of infection occurs in young people, but in older age, especially in patients with cardiovascular and bronchopulmonary pathology, it can cause hospitalization, including emergency [30]. Vascular Endothelial Growth Factor (VEGF)-activator of angiogenesis, responsible for restoring oxygen supply to tissues in a situation where blood circulation is insufficient. In physiological concentrations, endothelin (ET) acts on endothelial receptors, causing the release of relaxation factors, in higher concentrations it activates receptors on smooth muscle cells, stimulating persistent vasoconstriction primarily at the level of microcirculation [19]. The constrictor activity of endothelin-1 may be a factor of vasospasm enhancement, closing the vicious circle of pathobiochemical reactions and aggravating cerebral ischemia [9].

In our studies, the study of VEGF concentration showed a tendency to increase, regardless of nosology, to 40.05 ± 1.49 and 42.15 ± 1.82 in relation to control- 38.47 ± 2.23 in newborns with critical conditions of the 1st and 2nd groups, respectively (Table 1). The established phenomenon indicates the involvement in the development of CVD during the first 5 days in newborns of the observed group both with coronavirus infection and with PDCNS in the absence of COVID-19.

To reduce invasive manipulations and compare blood serum and urine values in newborns of the observed group, urocytokinodiagnostics was performed.

The studied indicators in urine allowed us to conclude that during the first 5 days of life of full-term newborns with perinatal pathologies, reliable results of urocytokinodiagnostics can be obtained. Thus, in full-term newborns with perinatal pathologies, the concentrations of INF γ , IFN α and IL-17A significantly increase in urine both during infection and in the absence of COVID-19 in the mother. The studies revealed a statistically significant 3-fold increase in the level of INF γ to 16.84 ± 0.66 pg/ml in children of group 1, and a 2-fold increase (10.21 ± 0.41 pg/ml) in children of group 2, against the control- 5.94 ± 0.23 pg/ml ($p < 0.05$). This tendency to increase was noted in relation to the level of IFN α in urine: up to 7.60 ± 0.39 pg/ml and 9.49 ± 0.43 pg/ml against the control- 5.78 ± 0.23 pg/ml, in newborns of the 1st and 2nd groups, respectively (Table 2).

TABLE 2 THE CONTENT OF CYTOKINES IN THE URINE OF NEWBORNS

Immunologic parameters of urine	Control group n=31		1-group n=33		2-group n=30	
	min-max	Average	min-max	min-max	Average	min-max
IFN γ	4,25-8,75	5,94 \pm 0,23	10,08-24,11	16,84 \pm 0,66*	6,94-15,42	10,21 \pm 0,41*
IFN α	3,68-8,06	5,78 \pm 0,23	4,33-11,87	7,60 \pm 0,39*	5,48-14,33	9,49 \pm 0,43*
IL-17A	20,05-38,48	30,75 \pm 0,93	41,15-92,50	65,48 \pm 2,30*	23,55-54,67	37,07 \pm 1,43*
MCP-1	74,51-130,2	99,25 \pm 2,63	16,72-33,10	23,36 \pm 0,75*	39,45-71,27	54,75 \pm 1,80*
VEGF	18,36-34,97	26,99 \pm 0,87	10,26-30,15	19,79 \pm 1,02*	14,48-33,05	22,72 \pm 0,96*

Note: *-significantly relative to the control ($p < 0.05$)

The study of the concentration of MSR-1 in urine revealed a 4-fold decrease to 23.36 \pm 0.75 pg/ml in COVID-19 and a 2-fold decrease to 54.75 \pm 1.80 pg/ml in full-term neonates against control-99.25 \pm 2.63 pg/ml. And the concentration of VEGF in urine also had a significant tendency to decrease to 19.79 \pm 1.02 pg/ml and 22.72 \pm 0.96 pg/ml against the control -26.99 \pm 0.87 pg/ml, which indicates the absence of an activator for oxygen delivery to tissues and inadequate renal circulation during the first 5 days of life of full-term newborns both in the presence of COVID-19 and in its absence in newborns with PDCNS, respectively.

CONCLUSION

The obtained results of cytokinodiagnostics allowed early diagnosis and prediction of the health status of newborns for the development of critical conditions.

Newborns born from a mother with COVID-19 develop CVD during the first 5 days of life. In critical conditions in newborns with a coronavirus load, an increase in the synthesis of INF γ and IFN α was found against the background of an increase in the level of IL-17A, which confirms the activation of phagocytosis and interferon synthesis for the first time 5 days of life.

The established processes are accompanied by an increase in the level of MCP-1 in the blood by 3.89 times, with a decrease in its urine by 4.25 times in newborns born from a mother with COVID-19, which indicates the severity of the course of CVD. Both with COVID-19 infection and with PDCNS in newborns without COVID-19 infection, there is a tendency to increase VEGF in the blood, against the background of a statistically significant decrease in its urine. Consequently, the observed dynamics of cytokines in the blood and urine of newborns with CVD indicates the activation of phagocytosis, interferon formation and inadequate renal circulation during the first 5 days of life.

REFERENCES

1. Bakhranova N.R., Yuldasheva G.G. (2021). Pathogenetic Aspects Of Coronavirus Infection In Pregnant Women. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES, 64-69. <https://doi.org/10.47494/cajmns.vi0.351>
2. GanievaSh.Sh., Radzhabova G.B. Clinical And Laboratory Assessment Of The Health Status Of Patients With Chronic Obstructive Pulmonary Disease Who Have Undergone Coronavirus Infection. CAJMNS [Internet]. 2021Oct.18 [cited 2021Oct.28];:76-0. Available from: <http://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/353>
3. Ershov, F.I. Interferons and their inductors/F.I. Ershov, O.I. Iselev //Moscow: GEOTAR, 2005.-368 p.
4. Zhuravleva L.N. Interferon System In Premature Newborns With Congenital Pneumonia And Respiratory Distress Syndrome//Protection of motherhood and childhood No.1 (31) 2018.- p.5-8.
5. Monocytic Chemotactic Protein\1 In Physiology And Medicine K.A. Kolotov1*, P.G. Rasputin2 Perm Medical Journal No.3. volume XXXV,-2018. DOI 10.17816/pmj35399%105.
6. NavruzovaSh.I., Khamraeva D.R. Regional Features Of The Spread Of Chronic Constipation In Children // Eurasian Bulletin of Pediatrics. — 2021; 2 (9): 76-82. <https://cutt.ly/XWRsfvZ>
7. Nasonov EL, Denisov LN, Stanislav ML. Interleukin 17 is a new target for anti-cytokine therapy of immuno-inflammatory rheumatic diseases. Scientificandpracticalrheumatology. 2013;51(5):545–52
8. 2013;51(5):545–52
9. Neonatology–National Guidelines / ed. aka demika RAMS prof. N.N. Volodina. -M.: GEOTAR-Media, 2008. -749 p.
10. StepanovaYu.I., Gonchar I.A. Endothelin-dependent effects
11. in cerebrovascular pathology of ischemic genesis, Medical news. - 2013. - No. 10. - pp. 12-18.
12. Alserehi H, Wali G, Alshukairi A, Alraddadi B. Impact of Middle East Respiratory Syndrome coronavirus (MERS- CoV) on pregnancy and perinatal outcome. BMC Infect Dis. 2016;16:105. [PMC free article] [PubMed] [Google Scholar]
13. Amatya S, Corr TE, Gandhi CK, Glass KM, Kresch MJ, Muijsce DJ, Oji-Mmuo CN, Mola SJ, Murray YL, Palmer TW, Singh M, Fricchione A, Arnold J, Prentice D, Bridgeman CR, Smith BM, Gavigan PJ, Ericson JE, Miller JR, Pauli JM, Williams DC, McSherry GD, Legro RS, Iriana SM, Kaiser JR. Management of newborns exposed to mothers with confirmed or suspected COVID-19. J Perinatol. 2020 Jul;40(7):987-996. doi: 10.1038/s41372-020-0695-0. Epub 2020 May 21. PMID: 32439956; PMCID: PMC7241067.
14. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-815. doi:10.1016/S0140-6736(20)30360-3PubMedGoogle ScholarCrossref

15. Chen Rong, Zhang Yuan, Huang Lei, Cheng Bi-heng, Xia Zhong-yuan, Meng Qing-tao. Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*. 2020;67(6):655–663. [PMC free article] [PubMed] [Google Scholar]
16. Cruz AT, Zeichner SL. COVID-19 in children: initial characterization of the pediatric disease [published online ahead of print March 16, 2020]. *Pediatrics*. <https://doi.org/10.1542/peds.2020-0834>. [PubMed]
17. Cui Yuxia, Tian Maolu, Huang Dong, Wang Xike, Huang Yuying, Fan Li, Wang Liang, Chen Yun, Liu Wenpu, Zhang Kai, Wu Yue, Yang Zhenzhong, Tao Jing, Feng Jie, Liu Kaiyu, Ye Xianwei, Wang Rongpin, Zhang Xiangyan, Zha Yan. A 55-Day-Old Female Infant Infected With 2019 Novel Coronavirus Disease: Presenting With Pneumonia, Liver Injury, and Heart Damage. *The Journal of Infectious Diseases*. 2020;221(11):1775–1781. [PMC free article] [PubMed] [Google Scholar]
18. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. *JAMA*. 2020. 10.1001/jama.2020.4621. [PMC free article] [PubMed]
19. Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, et al. Perinatal transmission of COVID-19 associated SARS-CoV-2: should we worry? *Clin Infect Dis*. 2020. 10.1093/cid/ciaa226. [PMC free article] [PubMed]
20. Gaffen SL. Structure and signalling in the IL-17 receptor family. *Nat Rev Immunol*. 2009;9(8):556–67. DOI: <http://dx.doi.org/10.1038/nri2586>.
21. Kawanabe Y., Nauli S.M. // *Cell. Mol. Life Sci.*–2011. – Vol.68 (2). – P.195–203,
22. Kimberlin DW, Stagno S. Can SARS-CoV-2 infection be acquired in utero? More definitive evidence is needed. *JAMA*. 2020. 10.1001/jama.2020.4868. [PubMed]
23. Kollmann T.R., Kampmann B., Mazmanian S.K., Marchant A., Levy O. Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. *Immunity*. 2017;46:350–363. [PubMed] [Google Scholar]
24. Kushnareva, M. The use of intravenous immunoglobulins in premature newborn children in hardware lung ventilation / M. Kushnareva, E. Vetrova, G. Dementyeva // *Int. J. Medical Science*. –2014.–Vol. 5.–№2.–P. 23–25
25. Liu P, Zheng J, Yang P, Wang X, Wei C, Zhang S, Feng S, Lan J, He B, Zhao D, Li J, Zhang Y. The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China. *J Allergy Clin Immunol*. 2020 Jul;146(1):101-109.e1. doi: 10.1016/j.jaci.2020.04.038. Epub 2020 May 11. PMID: 32437740; PMCID: PMC7211641.
26. Liu W, Wang Q, Zhang Q, Chen L, Chen J, Zhang B, et al. Coronavirus disease 2019 (COVID-19) during pregnancy: a case series. *Preprints*. 2020;2020020373.
27. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395:565–74. [PMC free article] [PubMed] [Google Scholar]

28. Mullins E., Evans D., Viner R. M., O'Brien P., Morris E. Coronavirus in pregnancy and delivery: rapid review. *Ultrasound in Obstetrics & Gynecology*. 2020;55(5):586–592. [PubMed] [Google Scholar]
29. NavruzovaSh.I, Akhmedov A.T. Autoimplantation Of Thymus In Surgical Correction Of Congenital Heart Defects . *Cajmns* [Internet]. 2021May26 [cited 2021Oct.28]; 2(3):88-. Available from: <http://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/178>
30. Schaller B.J. // *Arch. Med. Sci.* – 2006. – Vol.2, 3. –P.146–158 .
31. Schwartz D.A., Graham A.L. Potential maternal and infant outcomes from coronavirus 2019-nCoV (SARS-CoV-2) infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. *Viruses*. 2020;12:194. [PMC free article] [PubMed] [Google Scholar]
32. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol*. 2016; 24 (6): 490–502. DOI: 10.1016/j.tim.2016.03.003
33. Wang L, Shi Y, Xiao T, Fu J, Feng X, Mu D, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition) *Ann Transl Med*. 2020;8:47. [PMC free article] [PubMed] [Google Scholar]]
34. Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, et al. A case report of neonatal COVID-19 infection in China. *Clin Infect Dis*. 2020. 10.1093/cid/ciaa225.
35. Yuldasheva Gulnoz Giyasovna, Bakhranova Nasiba Ramazanovna, & Baratov Sunnat Samiyevich. (2021). Statistical Analysis Of The Structure Of The Birth Rate Of Underweight Children In The Bukhara Region. *Art of Medicine International Medical Scientific Journal*, Volume-1(Issue-2), 73–81. <https://doi.org/10.5281/zenodo.5155178>
36. Zeng L, Xia S, Yuan W, Yan K, Xiao F, Shao J, Zhou W. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr*. 2020 Jul 1;174(7):722-725. doi: 10.1001/jamapediatrics.2020.0878. PMID: 32215598; PMCID: PMC7099530.
37. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr*. 2020;9 (1):51-60. doi:10.21037/tp.2020.02.06PubMedGoogleScholarCrossref
38. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. *Clin Sci*. 2012;122(11):487–511. DOI: <http://dx.doi.org/10.1042%2FCS20110496>